|Videos|September 14, 2018

Flu Shot: Debunking Common Misconceptions

Mindy Smith, BSPharm, RPh, shares common misconceptions about the flu shot and how providers can advocate for the vaccination to their patients.

Segment Description: Mindy Smith, BSPharm, RPh, VP of Pharmacy Practice Innovation, PrescribeWellness, shares common misconceptions about the flu shot and how providers can advocate for the vaccination to their patients.

Interview Transcript (modified slightly for readability):

“I, as a pharmacist, even have these types of conversations with my friends, neighbors, and family, where there is a misperception of a couple things. One, that you can get the flu from the flu shot, which is absolutely impossible, because the flu vaccine actually has dead virus in it. You can only get the flu from a live virus. Secondly, there also is a misperception from a public perspective, that because the flu vaccine may not cover the entire strain that comes out in the flu season they just don’t need it. They’re going to take their chances and not get the vaccine, where I always advocate—and pharmacists can play a role in advocating for patients—you cannot get the flu no matter what from getting the vaccine.

Now, were you exposed to the vaccine and did it lower your immune system, and then you got the flu? Yes, but you cannot get it directly. But two, I always give your Vegas chances. Why wouldn’t you lower yours? Instead of having an 100% chance of catching the flu, you can lower that to 50%, 60%, 80%, depending on the coverage of the strain for that season—why wouldn’t you do that? And so, I always say, ‘Go get it. I don’t care; I don’t want to hear about it. Go get your flu shot.’”


Related to this article

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.